Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ATYR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Delisting (new) — Company faces potential delisting from Nasdaq if it fails to maintain $1.00 minimum bid price by November 30, 2026.
aTyr Pharma gets 180-day extension to regain Nasdaq compliance or face delisting
Filed June 8, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Nasdaq granted extension until Nov 30, 2026 to meet $1.00 minimum bid price requirement; company may use reverse stock split if needed to avoid delisting
Item 3.01 verify on EDGAR → -
medium
Stock must close at or above $1.00 for 10 consecutive business days (potentially 20 at Nasdaq's discretion) to regain compliance
Item 3.01 verify on EDGAR → -
high
Original deficiency notice received Dec 4, 2025 after stock traded below $1.00 for 30 consecutive days; first 180-day period expired June 2, 2026 without compliance
Item 3.01 verify on EDGAR → -
high
If compliance not achieved by deadline, Nasdaq will initiate delisting proceedings; company can appeal but success not guaranteed
Item 3.01 verify on EDGAR →
Summary
aTyr Pharma received a critical 180-day extension from Nasdaq on June 3, 2026, giving the biotech company until November 30, 2026 to regain compliance with the exchange's $1.00 minimum bid price requirement. This is the company's second compliance period after its stock traded below $1.00 for 30 consecutive business days starting in late 2025.
The company has indicated it may execute a reverse stock split if necessary to meet the requirement. Retail investors should understand that delisting risk is now material and immediate. If the stock fails to close at or above $1.00 for at least 10 consecutive business days before the November deadline, Nasdaq will move to delist the shares.
While the company could appeal, delisting would severely impact liquidity and make the stock harder to trade, potentially forcing it to over-the-counter markets. Watch for any announcement of a reverse stock split in coming months, which would be the clearest signal management is taking action to preserve the Nasdaq listing. Also monitor whether the stock can sustain any price recovery above $1.00, as ten consecutive days of compliance would resolve the issue entirely.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026, the Company received a letter from the Staff (the “Letter”) notifying the Company that the Company is eligible for an additional 180-day period, or until November 30, 2026 (the “Compliance Date”), to regain compliance, based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary.
Nasdaq granted aTyr Pharma an additional 180 days (until November 30, 2026) to regain compliance with the $1.00 minimum bid price requirement. The company indicated it may use a reverse stock split if necessary to cure the deficiency. This is the second compliance period after the initial 180-day period expired on June 2, 2026.
Added in current filing · verify on EDGAR →
on December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a) (2).
The company originally received notice on December 4, 2025 that its stock had traded below $1.00 per share for 30 consecutive business days, violating Nasdaq's minimum bid price requirement. The company was given until June 2, 2026 to regain compliance but did not meet that deadline.
Added in current filing · verify on EDGAR →
If the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company’s common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful.
If aTyr Pharma fails to meet the minimum bid price requirement by November 30, 2026, Nasdaq will initiate delisting proceedings. The company would have the right to appeal to a hearings panel, but success is not guaranteed. Delisting would likely reduce liquidity and investor access to the stock.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify